Chugai Pharma traded at 6,933.00 this Friday August 14th, decreasing 242.00 or 3.37 percent since the previous trading session. Looking back, over the last four weeks, Chugai Pharma lost 2.74 percent. Over the last 12 months, its price rose by 11.05 percent. Looking ahead, we forecast Chugai Pharma to be priced at 6,604.38 by the end of this quarter and at 5,709.05 in one year, according to Trading Economics global macro models projections and analysts expectations.
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.